ASCO GU On-Site Report | Prof. Xinan Sheng: A China-Developed Targeted–Immunotherapy Combination Opens a New Era of Bladder-Preserving Treatment for MIBC

ASCO GU On-Site Report | Prof. Xinan Sheng: A China-Developed Targeted–Immunotherapy Combination Opens a New Era of Bladder-Preserving Treatment for MIBC

The treatment landscape for muscle-invasive bladder cancer (MIBC) is undergoing profound transformation. Although cisplatin-based neoadjuvant chemotherapy remains the traditional standard of care, the pathological complete response (pCR) rate has long remained at approximately 30%–40%, and a substantial proportion of patients cannot receive cisplatin due to factors such as renal insufficiency. Consequently, more effective preoperative treatment strategies are urgently needed.
ASCO GU On-Site Report | Prof. Zhisong He Discusses Post-Immunotherapy Challenges in Advanced Renal Cancer and the Future of Precision Combination Therapy in Prostate Cancer

ASCO GU On-Site Report | Prof. Zhisong He Discusses Post-Immunotherapy Challenges in Advanced Renal Cancer and the Future of Precision Combination Therapy in Prostate Cancer

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), Chinese investigators once again made a strong impact on the international stage. Immunotherapy combined with targeted therapy has become the mainstream treatment paradigm for advanced renal cell carcinoma. However, key clinical questions remain unresolved worldwide, particularly how to optimize treatment strategies after immune-oncology (IO) therapy failure and how to rationally sequence or combine therapies in the era of multiple available agents.
ASCO GU On-Site Report | Prof. Bo Dai: Multiple Studies from Our Team Presented at an International Meeting, Opening New Pathways for Prostate Cancer Diagnosis and Treatment

ASCO GU On-Site Report | Prof. Bo Dai: Multiple Studies from Our Team Presented at an International Meeting, Opening New Pathways for Prostate Cancer Diagnosis and Treatment

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) has successfully concluded. As the premier annual academic event in the field of genitourinary oncology, the meeting brought together leading experts from around the world and showcased numerous cutting-edge studies and breakthroughs with the potential to reshape clinical practice.
Deep Responses Reshaping First-Line Standards | Prof. Qiang Dong Discusses the LIBERTAS China Subgroup Results Presented at ASCO GU 2026

Deep Responses Reshaping First-Line Standards | Prof. Qiang Dong Discusses the LIBERTAS China Subgroup Results Presented at ASCO GU 2026

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) was held in San Francisco, USA, from February 26 to 28, showcasing some of the most innovative scientific advances in the field and exploring future directions in the treatment of genitourinary malignancies. In recent years, research and clinical practice in urologic oncology in China have advanced rapidly. More than 70 studies led by Chinese experts and investigators were presented at the meeting. Among them, the Department of Urology at West China Hospital of Sichuan University contributed 10 studies, including six in prostate cancer, two in upper tract urothelial carcinoma, and two in renal cell carcinoma, highlighting the growing impact of Chinese research on the global stage.
ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice globally.
JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

In real-world clinical practice, a considerable proportion of patients with multiple myeloma (MM) are unable to tolerate autologous stem cell transplantation (ASCT) due to advanced age, comorbidities, or poor performance status, creating an urgent need for more effective therapeutic strategies. On February 27, 2026, a research paper entitled Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) by a Chinese research team was published online in the Journal of Clinical Oncology (IF=43.4). This study provides the first prospective clinical evidence for the field, confirming that the upfront application of B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to transplantation—including those with high-risk disease—achieves an impressive 100% minimal residual disease (MRD) negativity rate and a 94.4% complete response rate (CRR) with a favorable safety profile. This novel therapeutic approach is expected to establish a new paradigm for MM treatment. This article summarizes the key findings of this landmark study for clinical reference.
A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

Everything that has passed is but a prelude. Reflecting on the progress made in urologic oncology in 2025, the field witnessed the release of numerous landmark study results alongside a series of high-level international conferences. These developments have significantly expanded the boundaries of knowledge and provided invaluable platforms for researchers worldwide to exchange ideas and strengthen collaboration.
Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Prostate cancer remains the most prevalent genitourinary malignancy among men worldwide. Early and accurate diagnosis is fundamental to comprehensive disease management, long-term survival improvement, and reduction of the societal burden of disease. As the pathological gold standard for prostate cancer diagnosis, biopsy continues to serve as the central arena for technological innovation and clinical investigation in precision oncology.
Annual Review | Dawn in the “Bladder Preservation Battle”: Prof. Yijun Shen Reviews Key Advances in NMIBC in 2025

Annual Review | Dawn in the “Bladder Preservation Battle”: Prof. Yijun Shen Reviews Key Advances in NMIBC in 2025

The year 2025 marked a pivotal turning point in the management of urothelial carcinoma (UC). Nowhere has this transformation been more striking than in high-risk non–muscle-invasive bladder cancer (NMIBC), where long-standing limitations of bacillus Calmette–Guérin (BCG) therapy are finally being challenged by innovative strategies—most notably immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs).